 |
18 Diseases |  |
0 Trials |
|
0 Trials |  |
32 News |  |
- | bradanicline (ATA-101) / CODA Biotherap
Retrospective data, Journal: Diagnostic utility of HFLC% and IG% for acute Pancreatitis-A retrospective Case-Control study. (Pubmed Central) - May 6, 2024
We divided patients in the Non-MAP group with complete data(101 patients) into HFLC%
- | encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe, bradanicline (ATA-101) / CODA Biotherap
Journal: Characterizing the binding of TC-5619 and encenicline on the alpha7 nicotinic acetylcholine receptor using PET imaging in the pig. (Pubmed Central) - Apr 11, 2024
Of particular significance, our in vivo investigations demonstrate that TC-5619 achieves substantial ?7-nAChR occupancy, effectively blocking approximately 40% of ?7-nAChR binding, whereas encenicline exhibits more limited ?7-nAChR occupancy. This study underscores the importance of preclinical PET imaging and target engagement analysis in informing clinical trial strategies, including dosing decisions.
- bradanicline (ATA-101) / CODA Biotherap
Optimizing Novel Chemogenetic Tools to Control Focal Seizures (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1437;
Our data show that chimeric chloride channels, like the CODA71 receptor, allow targeted focal seizure suppression, while avoiding potential pitfalls of systemic and DREADD-based therapies. We continue to explore how further restricting receptor expression to more select neuronal subsets or altering sensitivity to endogenous ACh signaling can further improve the potential of this approach to treat focal epilepsies.
- bradanicline (ATA-101) / CODA Biotherap
Inhibition of neuronal activity using a novel chemogenetic platform developed for the treatment of neurological disorders (SDCC Halls B-H) - Oct 10, 2022 - Abstract #Neuroscience2022NEUROSCIENCE_5083;
The dose-response relationship and current amplitudes of TC-5619 (TC) and acetylcholine (ACh) were assessed in CODA receptor-expressing HEK293 (HEK) cells and in primary neonatal mouse hippocampal (mHC) neurons... Optimization of engineered CODA receptors for desired properties can increase the safety and effectiveness of CODA Biotherapeutics’ chemogenetics-based therapeutic approach for neurological disorders.
- | bradanicline (ATA-101) / CODA Biotherap
Journal: Evidence for alpha nicotinic receptor activation during the cough suppressing effects induced by nicotine and identification of ATA-101 as a potential novel therapy for the treatment of chronic cough. (Pubmed Central) - Feb 17, 2022
Significance Statement This study documents the antitussive actions of nicotine and identifies the α nicotinic receptor subtype as the target for nicotine during cough suppression described in humans. We additionally present evidence suggesting that ATA-101 and other α nicotinic receptor selective agonists may be promising candidates for the treatment of chronic refractory cough.
- bradanicline (ATA-101) / CODA Biotherap
Controlling focal seizures using novel chemogenetic tools () - Dec 12, 2021 - Abstract #AES2021AES_1651;
Our data demonstrate the potential of the Coda71 receptor, and other similar chimeric chloride channel variants, to allow targeted focal seizure suppression, while avoiding potential pitfalls of systemic and DREADD-based therapies. We aim to determine whether further restricting receptor expression to more select neuronal subsets or altering sensitivity to endogenous cholinergic signaling can further improve the potential of our approach to treat focal epilepsies.
- || bradanicline (ATA-101) / CODA Biotherap
Thank you. It doesn't make sense to me without some more details. Is it not Statistics/Data 101 to include variable scales? The graphic seems to 'fit the belief" rather than represent truth (Twitter) - Mar 24, 2021
- ||| hydroxychloroquine / Generic mfg., bradanicline (ATA-101) / CODA Biotherap
Clinical data: Good, bc the FDA could have been a little more stringent with their evaluation when they gave hydroxychloroquine the EUA on anecdotal data and maybe the FDA official should have known clinical data 101 before misrepresenting data. https://t.co/Kmv1HsNqBs (Twitter) - Sep 10, 2020
- bradanicline (ATA-101) / CODA Biotherap
[VIRTUAL] The Efficacy of Bradanicline in Refractory Chronic Cough (Channel 2) - Jul 15, 2020 - Abstract #ERS2020ERS_4646;
We aim to determine whether further restricting receptor expression to more select neuronal subsets or altering sensitivity to endogenous cholinergic signaling can further improve the potential of our approach to treat focal epilepsies. Despite good tolerability, escalating doses of bradanicline did not reduce awake cough frequency in RCC patients compared with placebo.
- || bradanicline (ATA-101) / CODA Biotherap
Trial completion, Trial completion date, Trial primary completion date: A Dose Escalation Study of Bradanicline in Refractory Chronic Cough (clinicaltrials.gov) - Jun 20, 2019
P2, N=46, Completed, Sponsor: Attenua, Inc.
Despite good tolerability, escalating doses of bradanicline did not reduce awake cough frequency in RCC patients compared with placebo. Recruiting --> Completed | Trial completion date: Oct 2019 --> May 2019 | Trial primary completion date: Sep 2019 --> May 2019
- | bradanicline (ATA-101) / CODA Biotherap
Enrollment open: A Dose Escalation Study of Bradanicline in Refractory Chronic Cough (clinicaltrials.gov) - Nov 6, 2018
P2, N=46, Recruiting, Sponsor: Attenua, Inc.
Recruiting --> Completed | Trial completion date: Oct 2019 --> May 2019 | Trial primary completion date: Sep 2019 --> May 2019 Not yet recruiting --> Recruiting
- | bradanicline (ATA-101) / CODA Biotherap
New P2 trial: A Dose Escalation Study of Bradanicline in Refractory Chronic Cough (clinicaltrials.gov) - Aug 9, 2018
P2, N=46, Not yet recruiting, Sponsor: Attenua, Inc.
- ||| bradanicline (ATA-101) / CODA Biotherap
Enrollment change: Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia (clinicaltrials.gov) - Dec 5, 2013
P2, N=603, Completed, Sponsor: Targacept Inc.
Not yet recruiting --> Recruiting N=456 --> 603
- |||| bradanicline (ATA-101) / CODA Biotherap
Trial completion: Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia (clinicaltrials.gov) - Dec 5, 2013
P2, N=603, Completed, Sponsor: Targacept Inc.
N=456 --> 603 Active, not recruiting --> Completed
- ||| bradanicline (ATA-101) / CODA Biotherap
Enrollment change: Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD) (clinicaltrials.gov) - Apr 21, 2013
P2, N=250, Completed, Sponsor: Targacept Inc.
Active, not recruiting --> Completed N=152 --> 250
- |||| bradanicline (ATA-101) / CODA Biotherap
Trial completion: Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD) (clinicaltrials.gov) - Apr 21, 2013
P2, N=250, Completed, Sponsor: Targacept Inc.
N=152 --> 250 Active, not recruiting --> Completed
- ||||| bradanicline (ATA-101) / CODA Biotherap
New P2 trial: Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia (clinicaltrials.gov) - Dec 6, 2011
P2, N=603, Completed, Sponsor: Targacept Inc.
- ||||| bradanicline (ATA-101) / CODA Biotherap
New P2 trial: Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD) (clinicaltrials.gov) - Nov 15, 2011
P2, N=250, Completed, Sponsor: Targacept Inc.
- bradanicline (ATA-101) / CODA Biotherap
Enrollment change: Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease (clinicaltrials.gov) - Nov 8, 2011
P1, N=38, Completed, Sponsor: Targacept Inc.
Active, not recruiting --> Completed N=54 --> 38
- | bradanicline (ATA-101) / CODA Biotherap
Trial completion: Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease (clinicaltrials.gov) - Nov 8, 2011
P1, N=38, Completed, Sponsor: Targacept Inc.
N=54 --> 38 Active, not recruiting --> Completed